<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557778</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CBR-CRE-2007/1</org_study_id>
    <nct_id>NCT00557778</nct_id>
  </id_info>
  <brief_title>Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia</brief_title>
  <acronym>PRECAVER</acronym>
  <official_title>Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the benefit (rate of adherence to the treatment), based on the LDL-C reduction in
      the group that will be exposed to the program of reinforcement of orientation aimed to the
      patients, compared to the control group, both in previous use of rosuvastatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the LDL-C reduction in the group exposed to the educational program compared to the group with routine orientation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess cardiovascular risk through Framingham's score, · · Identify personal characteristics of the study population regarding their health, compile demographic characteristics regarding education, economic and cultural status.</measure>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Patients With Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects eligible for the treatment of dyslipidemia with statins according the current
             guidelines NCEP ATPIII and IV Brazilian Guidelines of Dyslipidemia and Atherosclerosis
             Prevention.

          -  Patients with previous use of rosuvastatin for, at least, 15 days and, for no longer
             than12 months prior to the inclusion in the study.

        Exclusion Criteria:

        Pregnancy and childbearing

          -  History of severe hypersensitivity (including myopathy) to other HMG-CoA reductase
             inhibitors.

          -  Subjects with indication of use of cyclosporine and other associations of other lipid
             lowering drugs.

          -  Subjects with underlying diseases that may influence lipid levels (i.e. uncontrolled
             hypothyroidism defined as a Thyroid stimulating hormone (TSH) &gt; 1.5 times upper level
             of normality (ULN) at Visit 1, AIDS, transplanted subjects, etc).

          -  History of drug and alcohol abuse.

          -  Current active liver disease or hepatic failure or elevations in ALT &gt;3 times the ULN.

          -  Elevation of CPK &gt; 3 times the ULN.

          -  Elevation in the seric creatinine &gt; 2,0 mg / dL.

          -  History of malignancy in the last 5 years, except basal cell or squamous cell
             carcinoma of the skin (women with a history of Cervical dysplasia must be included,
             unless they have t3 clear consecutive Papanicolaou (Pap) smears , before the entry in
             the study).

          -  Any other known clinical condition that, in the opinion of the investigator, may
             compromise the subject's safety.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Eduardo Neves, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Brazil Ltda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Jose Saraiva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PUC-Campinas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>April 27, 2011</last_update_submitted>
  <last_update_submitted_qc>April 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jose Eduardo Neves/Medical Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

